Clusterin, a 70-Kd disulfide-linked two-chain plasma glycoprotein circulates in blood as a high-density lipoprotein particle and is highly induced after tissue injury and tissue remodeling. In this study, peripheral blood leukocytes were assayed for clusterin expression. The protein was predominantly detectable in human platelets by immune cytochemistry. The content of clusterin was determined and amounts to 2.5 f 1.3 pg/109 platelets, thus representing about 2% of the blood pool. Clusterin purified from human platelets had the same molecular weight as plasma clusterin under nonreducing conditions and was composed of two disulfide-linked nonidentical subunits of the same UMAN CLUSTERIN (synonyms: complement lysis H inhibitor, CLI; sulfated glycoprotein 2, SGP-2; sp-40,40; testosterone-repressed prostatic messenger 2, TRPM-2; gp-111; apolipoprotein J, apo-J; gene name: CLI) was recently discovered as a integral component of the soluble C5b-9 complement which is assembled in the fluid phase (plasma) from the complement proteins C5b to C9 and vitronectin on activation of the complement cascade. Because binding of clusterin to terminal complement complexes at the stage of nascent C5b-7 complexes abolishes their membranolytic p~t e n t i a l , ' ,~,~ clusterin was also called CLI.
Like all other components of terminal complement complexes, clusterin circulates as a normal constituent in human blood plasma. Clusterin of plasma is specifically bound to high density lipoproteins (HDL) and may represent an important regulatory apolipoprotein (called apo-1) of H D L s .~, '~-'~ Besides liver and testis, the clusterin gene is expressed in many other tissues and in different cell types, including epithelial cells, eg, those lining the proximal tubules of the kidney,I5 neuronal cells,16 and in some cells of the diffuse endocrine system.17
Transcription of the gene is temporarily highly upregulated in regressing, involuting, regenerating, or injured tissues. Clusterin levels are significantly increased in embryologic tissues undergoing apoptosis," in Alzheimer's disease in the hippocampu~,'~ in epileptic foci,2o and in prostate2' and mammary glandz2 after hormone withdrawal. Thus, clusterin appears to be a transcript that is presumably involved in defensive responses to tissue damage and cellular injury. In view of its high inducibility in damaged tissues, clusterin has been regarded as a bona fide cell death marker."
The aim of this study was to determine whether clusterin is expressed and stored in circulating peripheral blood (PB) cells. Immunohistochemical studies showed its abundant presence in platelets, whereas other hematopoietic cell lineages were only slightly positive or negative. We report the biochemical properties and subcellular location of clusterin in a-granules and show by the method of in situ RNA:RNA hybridization that clusterin mRNA is most abundantly expressed in a subpopulation of immature megakaryocytes.
EXPERIMENTAL PROCEDURES
Triton X-100, enzyme inhibitors, and other common chemicals were all purchased from Sigma (Buchs, Switzerland). Phorbol myristate acetate (PMA), HEPES, and PIPES were obtained from Calbiochem (Laufelfingen, Switzerland).
Fresh platelet-rich plasma was obtained from the local blood center. Platelets were centrifuged at 500g for 20 minutes and resuspended in an equal volume of buffer containing 5 mmol/L PIPES, pH 6.8; 145 mmol/L NaCI; 4 mmol/L KCI; 0.5 mmol/L Na2HP0,; and 1 mmol/L EDTA. The washings were Chemicals.
Platelel preparation.
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Blow! VOI 82, NO Purrfieation of clusterin. Clusterin was purified from platelets using PMA-induced releasate obtained from washed platelets corresponding to 3 U of blood. The releasate was spun at 15,OOOg for 20 minutes. The supernatant was subjected to a immuno-affinity chromatography column (5 mL bed volume) with immobilized monoclonal anti-human clusterin antibodies' equilibrated in 10 mmol/L Tris HC1, pH 7.4, containing 150 mmol/L NaCl (TBS). The adsorbed proteins were washed with 50-mL TBS, containing 0.5 NaCI (final concentration). Clusterin was eluted with 0.2 mol/L glycine, pH 2.8, and the collected fractions were immediately neutralized with a I mol/L solution of Tris HCl, pH 8.0. Fractions containing clusterin antigen were determined using the enzyme-linked immunosorbent assay (ELISA) described below, dialyzed against TBS, and stored at -20°C until use.
An ELISA was used to quantify clusterin, which will be described in detail elsewhere. 23 In brief, wells of microtiter plates (Nunc, MAXISORP, Basel, Switzerland) were coated in the presence of 0.2% Tween-20 (Sigma Chemical Co, St Louis, MO). Whereas most proteins do not bind to the plastic in the presence of the detergent, clusterin is adsorbed in a dose-dependent fashion. Clusterin was detected using the mouse anticlusterin antibody CL1-9, followed by an anti-mouse IgG-peroxidase and the chromogenic substrate 2,2'-Azino-di-(3-ethyl-benzthiazolinsulfonic acid) (Boehringer, Mannheim, Germany) according to standard procedures.
In situ hybridization. to an average size of 50 to 100 nucleotides by mild alkaline hydrolysis as previously described.24
Human spinal bone marrow (BM) aspirates were smeared onto poly-L-lysine (Sigma) coated microscope slides, fixed in 4% glutaraldehyde in phosphate-buffered saline (PBS) for 4 minutes rinsed in PBS, and storedin 70% ethanol at 4°C until analyzed. In situ hybridizations were performed with minor modifications of the procedure previously de~cribed.'~ Briefly, 0.4 to 1 X IO6 cpm of ['HI-labeled cRNAs were applied to each section in 60 pL of hybridization mixture. After graded ethanol dehydration, sections were immersed in NTB-2 emulsion (Eastman Kodak, Lausanne, Switzerland), diluted 1:l in deionized water. After 12-to 15-week exposure, they were developed in Kodak D-19 developer, fixed in 30% Na-thiosulfate, and counterstained in methylene blue or May-Griinwald solution (Fluka, Buchs, Switzerland).
Hybridizations with sense RNA probes were performed as controls of specificity. For each experiment, control tissue sections of human testes were also included, the Sertoli cells containing large amounts of clusterin mRNA. Microphotographs were taken with a photomicroscope (Zeiss, Oberkochen, Germany), equipped with Quantijication of clusterin in solubilized platelets.
an immersion dark-field condensor, using Kodak Ektachrome 50 color film.
Immunohistochemistry. For immunoperoxidase stainings, freshly isolated platelets were cytocentrifuged at 600 rpm for 10 minutes allowed to dry, and kept at room temperature overnight.
The cells were permeabilized with 0. I% Triton X-100. A three layer biotin-avidin-peroxidase technique was used25 in combination with monoclonal antibodies (MoAbs) to human clusterin (CLI-9). The peroxidase activity was shown with the chromogen 3-amino-9-ethylcarbazol."
Immuno-electronmicroscopy. Washed human platelets (2 X I 08/mL) from hirudin-supplemented blood were prefixed with 50 mL fixative (6% paraformaldehyde, 0.1% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.2). After centrifugation, the pellets were postfixed with 3% paraformaldehyde, 0.1% glutaraldehyde in phosphate buffer, washed, and resuspended in a solution containing 7.5% (wt/vol) polyvinylpyrrolidone K25 (Fluka AG, Buchs, Switzerland) and 2 mol/L sucrose in PBS. For inclusion, droplets of platelet-rich suspensions were placed on 5% gelatine at 3 7 T , and after cooling, blocks were plunge-frozen in liquid propane at -180°C (KF80; Reichert, Vienna, Austria). Ultrathin frozen sections (FC4 D; Reichert-Jung, Vienna, Austria) were mounted with 2.3 mol/L sucrose droplets on pioloform-coated Ni-grids.
After washing in PBS containing 0.05 mol/L glycine, the grids were incubated with primary antibody AC8 (IgG rabbit-antihuman clusterin; 5 pL/100 pL PBS) for 60 minutes at 20°C. After washing with PBS containing 0.5% (wt/vol) bovine serum albumin (BSA) (Aurion/Biotrend, Koln, Germany), secondary labeling with goat antibody (IgG goat-antirabbit GAR EM IO; Aurion/Biotrend; 20 pL/mL PBS) was performed for 60 minutes at 20°C. Finally, the grids were stained with 2% (wt/vol) ammoniummolybdate. Controls were done with rabbit IgG antihuman fibrinogen (Dakopatts, Hamburg, Germany) as primary antibody or without primary antibody.
Other methods. Gel electrophoretic analysis was performed according to L;immli,z6 using 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels. After electrophoresis, proteins were transferred onto nitrocellulose using the buffer system of Towbin et aL2' Immunoblots were processed using the alkaline-phosphatase detection system. The apolipoprotein (apo) A-I specific rabbit antiserum was purchased from Behring (Zurich, Switzerland).
RESULTS
Association of clusterin with human platelets. Clus-
terin circulates in human plasma as an apoA-I containing HDL complex that most likely originates from human liver. These HDL-like complexes as well as clusterin found in seminal plasma have been extensively characterized. The clusterin gene is also transcribed in a regulated manner by resident cells ofother organ tissues in the extravascular compartment. To investigate the possible presence and storage of clusterin in circulating hematopoietic cells, immunocytochemistry on PB cells was performed using an indirect peroxidase technique. Two different clusterin-specific MoAbs yielded the same immunostaining pattern. The majority of leukocytes and erythrocytes were clusterin-negative (data not shown), whereas thrombocytes stained strongly positive after immune-peroxidase visualization of bound antibodies. When purified platelets were analyzed by immunocytochemistry, most cells scored positive (Fig 1) . The staining signal was highly specific and For personal use only. on October 23, 2017. by guest www.bloodjournal.org From Fig 1. lmmunostaining of clusterin in platelets. (A) Platelets purified from human blood were permeabilized and treated with a monoclonal anti-human clusterin antibody, biotinylated antimouse IgG, and avidin-peroxidase conjugate with appropriate washes. Palatelets are brightly labeled in contrast to the control in which the monoclonal anticlusterin antibody has been left out (B) or an isotype-matched irrelevant antibody (anti-T-cell receptor, data not shown) has been used. Original magnification X 300. Actii~ation-dependent rcJ/casc (f chisterin .finin plate/els. Different agonists were used to release clusterin from activated human thrombocytes. The CaZ' ionophore A23 187 at a concentration of 20 pmol/L led to the complete release of clusterin into the supernatant (Fig 2. R) . This treatment also led to the parallel release of platelet-factor 4 (data not shown). No remaining clusterin was detected in washed pellets (Fig 2, P) after degranulation. Almost 100% release was Clu P R P R P R F T C l u R P kDa I also observed with different agonists. ie, 200 nmol/L PMA and IO nmol/L thrombin. Immunoblot analysis of the supernatant from activated platelets showed one band ofclusterin antigen. migrating at 70 Kd. indistinguishable from plasma-derived clusterin (Clu). The amount of antigen detected in the supernatant of thrombin-stimulated platelets (R) was similar to that obtained after freezing and thawing (Fig 2. F) or solubilization with 1% Triton X-100 (Fig 2, T ).
An
MoAb column was used to purify clusterin from platelets by affinity chromatography. PMA-induced releasates corresponding to 3 U of blood were harvested and passed over a clusterin-antibody affinity column. After extensive washing, platelet clusterin was eluted with a 0.2 mol/L glycine buffer, pH 2.8. as previously described for plasma clusterin. When the fractions were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) under nonreducing conditions followed by Coomassie blue staining (Fig 3A) . platelet clusterin migrated as a single band and showed the same apparent molecular weight of 70 Kd as the plasma-derived clusterin.
Purified platelet clusterin from fraction 13 (Platelet C) was further analyzed by immunoblot analysis under nonreducing (Fig 3B. NR) and reducing conditions (Fig 3B, R) . Without reduction. fraction 13 contained a single immunereactive protein of approximately 70 Kd that comigrated with plasma-derived clusterin. As shown in Fig 3B. clusterin from human platelets migrated in multiple. closely spaced bands of about 35 Kd after reduction with dithiothreitol (DTT), again similar to serum-derived clusterin that was shown to be proteolytically processed into two subunits of identical size during biosynthesis. However. a minor frac-
Isolation and cliaractcrization c?Splatelet clusterin.
For tion ofthe purified protein was resistant to reduction. probably representing incompletely processed precursor molecules of clusterin. The platelet and plasma forms of human clusterin differed strikingly in their molecular composition. As shown in Fig 3C, clusterin in human platelets is not associated with apoA-I, whereas clusterin of human plasma occurs as a stable HDL-like complex containing apoA-I. The 28-Kd band of apoA-I was detected only in plasma-derived clusterin, but was not detected in affinity-purified platelet clusterin by the sensitive technique of immunoblotting (Fig 3C) . Absence of apoA-I in preparations of platelet clusterin excludes the possibility that contaminating plasma is the source of platelet-associated clusterin. Preferential uptake of clusterin from human plasma or preferential loss of apoA-I into plasma seems unlikely because we failed to identify substoichiometric amounts of apoA-I in preparations of platelet clusterin.
A novel ELISA was used to measure the amount of clusterin in biologic samples. Platelets were washed in physiologic salt buffers and lysed in 0.2% Triton X-100. The amount of clusterin that adsorbs to microtiter plates after blocking with 0.2% Tween-20. was shown to be linear in the range between 5 ng/mL and 100 ng/mL clusterin and was quantitated immunologically with the use of peroxidase-conjugated antimouse antibodies. In control experiments in which an irrelevant MoAb was used. low background signals were obtained with platelet extracts. Standard curves were constructed with purified clusterin and plasma pools of healthy blood donors. In normal subjects. the clusterin content of human platelets amounts to 2.5 * I .3 &IO9 platelets (n = 5). PMA-induced releasates showed similar values (data not shown).
Loculizrrt ion of clir.sto.in in n-pun I ilcs f7.r irn in I inoc.lc.cIron tnicro.sc.opy. To identify the subcellular localization of clusterin in human platelets. acryl-embedded ultrathin sections of platelets were studied by immunoelectron microscopy using monoclonal anti-clustein antibodies in conjunction with immunogold-labeled second antibodies. Because of their characteristic density and size. n-granules were easily distinguishable from other types of platelet organelles. The cu-granules have diameters of approximately 300 nm. As can be seen in Fig 4. resting platelets with an oval section profile showed dense labeling in the n-granules. preferentially located in the periphery of the granules. whereas moderately dense labels were seen within the surface-connected membrane system. Labeling above background of the plasma membrane was also found. A similar pattern was observed for fibrinogen (Fig 4C) . Biosvnt l1c~si.s of' clr ist w i n bj nicyukurj*ocyt e x Because clusterin is a relatively abundant G P (50 to 100 pg/mL) in plasma and only a small portion of clusterin per milliliter blood is associated with washed platelets, we wondered whether clusterin is taken up into platelets from the plasma pool via the endocytic pathway as has been shown in the case of albumin. IgG. and fihronectin.'* or whether clusterin gene is actually synthesized and directly packaged into n-granules at a certain stage of megakaryocyte diferentiation. To establish clusterin transcription in platelet precursors, cytospin BM cell preparations were hybridized to a tritium [3H]-labeled clusterin cRNA probe. Specifically hybridizing transcripts were shown by emulsion autoradiography. Mature and intermediate megakaryocytes were identified by their morphology using light microscopy (Fig 5) . Expression ofclusterin mRNA was detected in a population of megakaryocytes with multilobed nuclei whose cytoplasm equaled the nucleus in size (Fig 5A and B) . Occasionally, cells with a bilobed or trilobed nucleus did not stain positive for clusterin mRNA. suggesting that in more immature megakaryocytes the clusterin mRNA is absent or scarce ( Fig  5C) . There was also little or no expression in platelets (data not shown). A low amount of clusterin expression was observed in and between other BM cells (Fig 5A. B. and C) . but the cell types expressing low amounts of clusterin have not been identified. Hybridization with the sense strand cRNA Qiiunlifitution ofpk11e4~1 c~lri.stc~tYn.
For probe generated significantly lower levels of silver grain density (Fig 5D) .
cytes to neuroendocrine cells. In this study. we identify clusterin in a-granules of platelets and show most abundant clusterin expression in a subpopulation of immature megakaryocytes using in situ RNA:RNA hybridization. Our observations strongly suggest that the clusterin gene is transcribed during megakaryocyte development at the ap- propriate stage that permits translation and packaging of proteins into a-granules. Thus. we established that in vivo megakaryocyte precursors possess the capacity to synthesize the clusterin that we identified in their cytoplasmic granules. Although not formally proven. our data support the view that clusterin is packaged into n-granules in conjunction with the transcription of the clusterin gene. Compared with the levels of clusterin circulating as an HDL complex
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in human plasma 1 (50 to 80 pg/mL), the amounts ofclusterin in platelets are relatively low and account for only 1 pg clusterin per milliliter of blood (4 X 10' platelets) that represents about 2% of total clusterin. At present, we cannot rule out the possibility that at least some clusterin is taken up through endocytosis of plasma clusterin.
Indirect evidence underscores the biologic significance of platelet clusterin. First of all, the concentration of clusterin within platelets is about fivefold higher than in human plasma. One milliliter of platelets (1.04 X IO") contains about 250 p g clusterin. About the same concentration has been reported for von Willebrand factor ( v W F ) ,~~ a biologically significant a-granule protein that is also synthesized by megakaryocytes. Secondly, clusterin of platelets is distinct from plasma clusterin in that it is not associated with apoA-I. Both findings strongly contradict the objection that clusterin could be sequestered into a-granules from plasma entirely through a mechanism of bulk flow endocytosis. Albumin or a I-antitrypsin that are known to follow this nonspecific route of entry have at least a IO-fold higher concentration in plasma than in platelets.29
Purification and characterization of platelet clusterin showed that its two-chain structure and glycosylation pattern is conserved between plasma and platelet clusterin. Clusterin is known to undergo intensive posttranslational glycosylation that may differ in certain tissues or cell types. For instance, the rat analogue of clusterin secreted by Sertoli cells and found in seminiferous tubule fluid is composed of monomers of M, 47,000 and 34,000, whereas the epididymal protein exhibits subunits of M, 40,000 and 29,000.30 Because molecular weight differences between the plasma and platelet form have not been detected by one-dimensional SDS-PAGE, we suggest that the glycosylation pattern of the two subunits of dusterin is similar, if not identical, with plasma clusterin. As for plasma clusterin, we found that a small fraction of the protein in a-granules is not processed into the two-chain form during biosynthesis. Thus, absence of proteolytic processing does not seem to prevent correct sorting and packaging of clusterin into platelets. Likewise, the single-chain form of clusterin has been reported to take the same apical route as the two-chain form in polarized Madin-Darby canine kidney (MDCK) cell^.'^ Platelet a-granules are the principal intracellular reservoir of proteins destined for release duringprimary hemostasis at the site of vessel wall injury. Many of these granule proteins contribute to tissue remodeling and wound healing. Clusterin was localized to these storage organelles as shown by electronmicroscopy after immuno-gold labeling of intracellular clusterin. This subcellular location is consistent with its release from platelets induced by different secretagogues such as thrombin, PMA, and ionophores. All of these stimulators triggered almost complete release into the extracellular medium.
Damage of the inner endothelial layer triggers platelet adhesion and release of platelet factors to the medial smooth muscle cells. As a response to platelet-and plasma-derived factors, smooth-muscle cells change their morphologic phenotype and migrate into the intima forming multi-layered nodules. These phenotypic alterations of smooth muscle cells in vivo resemble the morphologic transformation of cultured smooth muscle cells in vitro. As shown previ~u s l y ,~~ clusterin mRNA are low in monolayer cultures of smooth muscle cells, but increase strongly during formation of multilayers and muscle-cell nodules. Thus, local synthesis and secretion of clusterin is probably initiated in smooth muscle cells after activation and proliferation at the site of injury. Co-ordinate upregulation of clusterin by two independent delivery mechanisms, degranulation of platelets, and local de novo synthesis would be consistent with a putative biologic role in remodeling and regeneration of injured blood vessel walls.
However, how clusterin contributes to lesion repair at the biochemical level remains to be investigated. Clusterin, in particular the cell-derived form that is not associated with HDLs, may function as a local carrier for poorly soluble growth-promoting peptides or lipophilic substances. Alternatively, it may be involved in homotypic or heterotypic cell-to-cell interactions in view of its cell-aggregating activity. Because clusterin inhibits the assembly ofthe lytic terminal complement complex on cellular membranes, it may reduce complement activation at the site of vessel wall damage and may protect endothelial and smooth muscle cells from inappropriate complement attack.
